Browsing by Author "Arslan, G."
Now showing 1 - 10 of 10
- Results Per Page
- Sort Options
Item 1.5-Tesla Magnetic Resonance-Guided Adaptive Stereotactic Body Radiotherapy for Liver Malignancies(2023) Onal, C.; Yavas, G.; Yavas, C.; Arslan, G.; Efe, E.; Haberal, M.Item Comparison of IMRT and VMAT Plans with Different Energy Levels Using Monte Carlo Algorithm for Prostate Cancer(2014) Guler, O. C.; Onal, C.; Arslan, G.; Sonmez, S.; HOC-5611-2023Item Dose Escalation with Integrated Boost Using High-Field MR-LINAC in Prostate Cancer Patients(2023) Onal, C.; Arslan, G.; Yavas, C.; Efe, E.; Yavas, G.Item Dosimetric analysis of testicular doses in prostate radiotherapy at different energy levels(2016) Onal, C.; Arslan, G.; Dolek, Y.; Efe, E.Item Medical Risk and Benefit in Non-Renal Donors Living-Related Liver Transplantation in an Adult and a Child(Başkent Üniversitesi, 2008-06) Haberal, M.; Hamaloglu, E.; Koc, M.; Turan, M.; Uzunalimoglu, B.; Sert, S.; Gulay, H.; Karamehmetoglu, M.; Arslan, G.; Bayraktar, Y.; Kayhan, B.; Buyukpamukcu, N.; Bilgin, N.; Telatar, H.Item Novel Treatment Approach for Inoperable Bladder Cancer: 1.5 Tesla MRI-Guided Online Adaptive SBRT(2023) Yavas, G.; Yavas, C.; Efe, E.; Arslan, G.; Onal, C.Item Simultaneous Integrated Boost to Intraprostatic Lesions Using Different Energy Levels Of IMRT and VMAT(2014) Onal, C.; Guler, O. C.; Sonmez, S.; Erbay, G.; Arslan, G.; 0000-0002-1706-8680; HOC-5611-2023; AAK-5370-2021Item Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy(2014) Onal, C.; Sonmez, S.; Erbay, G.; Guler, O.C.; Arslan, G.Objective: This study compared the dosimetry of volumetric-arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT) with a dynamic multileaf collimator using the Monte Carlo algorithm in the treatment of prostate cancer with and without simultaneous integrated boost (SIB) at different energy levels. Methods: The data of 15 biopsy-proven prostate cancer patients were evaluated. The prescribed dose was 78 Gy to the planning target volume (PTV78) including the prostate and seminal vesicles and 86 Gy (PTV86) in 39 fractions to the intraprostatic lesion, which was delineated by MRI or MR-spectroscopy. Results: PTV dose homogeneity was better for IMRT than VMAT at all energy levels for both PTV78 and PTV86. Lower rectum doses (V-30-V-50) were significantly higher with SIB compared with PTV78 plans in both IMRT and VMAT plans at all energy levels. The bladder doses at high dose level (V-60-V-80) Were significantly higher in IMRT plans with SIB at all energy levels compared with PTV78 plans, but no significant difference was Observed in VMAT plans. VMAT plans resulted in a significant decrease in the mean monitor units (MUs) for 6,10, and 15 MV energy levels both in plans with and those without SIB. Conclusion: Dose escalation to intraprostatic lesions with 86 Gy is safe without causing Serious increase in organs at risk (OARs) doses. VMAT is advantageous in sparing OARs and requiring less MU than IMRT. Advances in knowledge: VMAT with SIB to intraprostatic lesion is a feasible method in treating prostate cancer. Additionally, no dosimetric advantage of higher energy is observed.Item Speckle Tracking Imaging For Evaluation Of Effects Of Peep Level On Right Ventricular Function(2015) Pirat, A.; Turker, M.; Firat, A. Camkiran; Pirat, B.; Sezgin, A.; Arslan, G.; 0000-0003-4576-8630; AAI-8897-2021Item Treatment Outcomes of 1.5 T MR-Guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancer(2023) Yavas, G.; Yavas, C.; Arslan, G.; Efe, E.; Onal, C.